Wednesday - February 11, 2026
GSK's RSV Vaccine, Arexvy, Accepted for Regulatory Review in China for Adults Aged 60 Years and Older
February 11, 2026
LONDON, England, Feb. 11 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Feb. 10, 2026:

* * *

GSK's RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older

* If approved, Arexvy will be the first vaccine available in China for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older

* RSV affects over six million . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products